Suri Technologies
Stealth mode
Health Tech & Life Sciences
Non Active, Dec 2019 ceased to operate
Company Overview
Snapshot
Founded in January 2014, Suri Technologies operated with 1–10 employees, with Ilan Hochman as a co-founder. The company focused on developing personalized cancer treatments using patient antibodies.
Business overview
Suri Technologies was dedicated to establishing a new field of anti-cancer treatment. The company focused on developing personalized cancer treatments by producing new personalized autoantibody drugs specifically tailored to each patient. Operating within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development, Suri Technologies aimed to serve the healthcare and life sciences industries with its innovative approach to oncology.
Log in to access full profile ›Company Intelligence Q&A
- What was Suri Technologies' primary focus?
- Suri Technologies focused on developing personalized cancer treatments by producing new personalized autoantibody drugs specifically for each patient, aiming to establish a new field of anti-cancer treatment.
- When was Suri Technologies founded?
- Suri Technologies was founded in January 2014.
- Who was a co-founder of Suri Technologies?
- Ilan Hochman was a co-founder and VP R&D at Suri Technologies.
- What was the operational status of Suri Technologies?
- Suri Technologies ceased to operate in December 2019.
- In which sector did Suri Technologies primarily operate?
- Suri Technologies primarily operated in the Health Tech & Life Sciences sector, with a focus on Pharma & Medical Biotechnology and Drugs Discovery & Development.